Tags

Type your tag names separated by a space and hit enter

De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset.
Mov Disord. 1998 Mar; 13(2):234-41.MD

Abstract

In contrast to levodopa (L-dopa), de novo administration of the D2-like receptor agonist bromocriptine to patients with Parkinson's disease (PD) or to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated subhuman primates is not associated with the onset of significant dyskinesia. We now compare the ability of the novel D2-like selective dopamine agonist ropinirole with that of bromocriptine and L-dopa to induce dyskinesia in MPTP-treated common marmosets. MPTP-treated common marmosets were treated with placebo, L-dopa plus carbidopa, ropinirole, or bromocriptine daily for 30 days (n = 4 per group) in doses that were titrated to similarly increase locomotion and improve motor disability. L-dopa rapidly induced dyskinesia of moderate to severe intensity, whereas ropinirole and bromocriptine produced mild dyskinesia over the course of the study that was significantly less severe than in the L-dopa-treated group (p < 0.05). However, in a separate group of marmosets previously primed with L-dopa to exhibit dyskinesia, ropinirole administration elicited severe dyskinesias comparable with that of L-dopa in a dose-dependent fashion. Ropinirole, in common with bromocriptine, has a lesser tendency than L-dopa to produce dyskinesia while similarly improving motor performance in drug-naive MPTP-treated marmosets. However, in common with other dopamine agonists, ropinirole will elicit comparable dyskinesia once L-dopa priming has occurred. These results predict a similar response to ropinirole and other long-acting dopamine agonists in L-dopa-naive patients with PD and emphasize the importance of avoiding initial dyskinesia induction through early use of dopamine agonist drugs.

Authors+Show Affiliations

Pearce RK
Neurodegenerative Diseases Research Centre, Biomedical Sciences Division, King's College , London, England.
Banerji T
No affiliation info available
Jenner P
No affiliation info available
Marsden CD
No affiliation info available

MeSH

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridineAnimalsAntiparkinson AgentsBromocriptineCallithrixDose-Response Relationship, DrugDrug Administration ScheduleDyskinesia, Drug-InducedFemaleIndolesLevodopaMaleMotor SkillsNeurologic ExaminationParkinson Disease, SecondaryReceptors, Dopamine D2

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

9539335

Citation

Pearce, R K., et al. "De Novo Administration of Ropinirole and Bromocriptine Induces Less Dyskinesia Than L-dopa in the MPTP-treated Marmoset." Movement Disorders : Official Journal of the Movement Disorder Society, vol. 13, no. 2, 1998, pp. 234-41.
Pearce RK, Banerji T, Jenner P, et al. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset. Mov Disord. 1998;13(2):234-41.
Pearce, R. K., Banerji, T., Jenner, P., & Marsden, C. D. (1998). De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset. Movement Disorders : Official Journal of the Movement Disorder Society, 13(2), 234-41.
Pearce RK, et al. De Novo Administration of Ropinirole and Bromocriptine Induces Less Dyskinesia Than L-dopa in the MPTP-treated Marmoset. Mov Disord. 1998;13(2):234-41. PubMed PMID: 9539335.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset. AU - Pearce,R K, AU - Banerji,T, AU - Jenner,P, AU - Marsden,C D, PY - 1998/4/16/pubmed PY - 1998/4/16/medline PY - 1998/4/16/entrez SP - 234 EP - 41 JF - Movement disorders : official journal of the Movement Disorder Society JO - Mov Disord VL - 13 IS - 2 N2 - In contrast to levodopa (L-dopa), de novo administration of the D2-like receptor agonist bromocriptine to patients with Parkinson's disease (PD) or to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated subhuman primates is not associated with the onset of significant dyskinesia. We now compare the ability of the novel D2-like selective dopamine agonist ropinirole with that of bromocriptine and L-dopa to induce dyskinesia in MPTP-treated common marmosets. MPTP-treated common marmosets were treated with placebo, L-dopa plus carbidopa, ropinirole, or bromocriptine daily for 30 days (n = 4 per group) in doses that were titrated to similarly increase locomotion and improve motor disability. L-dopa rapidly induced dyskinesia of moderate to severe intensity, whereas ropinirole and bromocriptine produced mild dyskinesia over the course of the study that was significantly less severe than in the L-dopa-treated group (p < 0.05). However, in a separate group of marmosets previously primed with L-dopa to exhibit dyskinesia, ropinirole administration elicited severe dyskinesias comparable with that of L-dopa in a dose-dependent fashion. Ropinirole, in common with bromocriptine, has a lesser tendency than L-dopa to produce dyskinesia while similarly improving motor performance in drug-naive MPTP-treated marmosets. However, in common with other dopamine agonists, ropinirole will elicit comparable dyskinesia once L-dopa priming has occurred. These results predict a similar response to ropinirole and other long-acting dopamine agonists in L-dopa-naive patients with PD and emphasize the importance of avoiding initial dyskinesia induction through early use of dopamine agonist drugs. SN - 0885-3185 UR - https://www.unboundmedicine.com/medline/citation/9539335/De_novo_administration_of_ropinirole_and_bromocriptine_induces_less_dyskinesia_than_L_dopa_in_the_MPTP_treated_marmoset_ L2 - https://doi.org/10.1002/mds.870130207 DB - PRIME DP - Unbound Medicine ER -